Hepatoprotective effects of misoprostol and silymarin on carbon tetrachloride-induced hepatic damage in rats

Fundamental and Clinical Pharmacology

Volumn 23, Issue 2, 2009, Pages 179-188

  Salam, Omar M E Abdel ^a   Sleem, Amany A ^a   Omara, Enayat A ^a   Hassan, Nabila S ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Acute hepatic injury; Misoprostol; Rat; Silymarin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; MISOPROSTOL; SILYMARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; LIVER INJURY; LIVER PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CARBON TETRACHLORIDE; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; GLYCOGEN; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MISOPROSTOL; NECROSIS; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SILYMARIN;

EID: 62849113069     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00654.x     Document Type: Article

References (56)

1. Patel K., Muir A.J., McHutchison J.G. Diagnosis and treatment of chronic hepatitis C infection. BMJ (2006) 332 1013 1017.
2. Manns M.P., McHutchison J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 358 958 965.
3. Fried M.W., Shiffman M.L., Reddy K.R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. (2002) 347 975 982.
4. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology (2002) 36 S237 S244.
5. Bacon B.R. Managing hepatitis C. Am. J. Manage. Care (2004) 10 S30 S40.
6. Saller R., Meier R., Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs (2001) 61 2035 2063.
7. Fraschini F., Demartini G., Esposti D. Pharmacology of Silymarin. Clin. Drug Invest. (2002) 22 51 65.
8. Boigk G., Stroedter L., Herbst H., Waldschmidt J., Riecken E.O., Schuppan D. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology (1997) 26 643 649.
9. Farghali H., Kamenikova L., Hynie S., Kmonickova E. Silymarin effects on intracellular calcium and cytotoxicity: a study in perfused rat hepatocytes after oxidative stress injury. Pharmacol. Res. (2000) 41 231 237.
10. Feher J., Lengyel G., Blazovics A. Oxidative stress in the liver and biliary tract diseases. Scand. J. Gastroenterol. (1998) 228 (Suppl.) 38 46.
11. Pares A., Planas R., Torres M. et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J. Hepatol. (1998) 28 615 621.
12. Trinchet J.C., Coste T., Lévy V.G. et al. Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients. Gastroenterol. Clin. Biol. (1989) 13 120 124.
13. Buzzelli G., Moscarella S., Giusti A., Duchini A., Marena C., Lampertico M. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int. J. Clin. Pharmacol. Ther. Toxicol. (1993) 31 456 460.
14. Gordon A., Hobbs D.A., Bowden D.S. et al. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J. Gastroenterol. Hepatol. (2006) 21 275 280.
15. Casado M., Callejas N.A., Rodrigo J. et al. Contribution of cyclooxygenase-2 to liver regeneration after partial hepatectomy. FASEB J. (2001) 15 2016 2018.
16. Schoen Smith J.M., Lautt W.W. The role of prostaglandins in triggering the liver regeneration cascade. Nitric Oxide (2005) 13 111 117.
17. Graham D.Y., White R.H., Moreland L.W. et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann. Int. Med. (1993) 119 257 262.
18. Park S.H., Cho C.S., Lee O.Y. et al. Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial-Storm Study. J. Clin. Biochem. Nutr. (2007) 40 148 155.
19. Flisiak R., Prokopowicz D. One year follow-up of patients treated with misoprostol in acute phase of viral hepatitis B. Prostaglandins Other Lipid Mediat. (2000) 60 161 165.
20. Bianchi G., Brizi M., Manini R. et al. Effects of long-term oral misoprostol administration on hepatic amino acid-nitrogen metabolism in patients with cirrhosis. J. Hepatol. (2002) 37 15 21.
21. Kornberg A., Schotte U., Kupper B., Hommann M., Scheele J. Impact of selective prostaglandin E1 treatment on graft perfusion and function after liver transplantation. Hepatogastroenterology (2004) 51 526 531.
22. Gatta A., Dante A., Del Gaudio M. et al. The use of prostaglandins in the immediate postsurgical liver transplant period. Transplant. Proc. (2006) 38 1092 1095.
23. Song J.S., Seo J.J., Moon H.N., Ghim T., Im H.J. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children. J. Korean Med. Sci. (2006) 21 897 903.
24. Hardy K.J., Tancheroen S., Shulkes A. Hepatic ischemia-reperfusion injury modification during liver surgery in rats: pretreatment with nifedipine or misoprostol. Liver Transpl. Surg. (1995) 1 302 310.
25. Flisiak R., Prokopowicz D., Lapiński W. Effect of misoprostol in ethanol-induced liver injury. Pol. J. Pathol. (1995) 46 187 190.
26. Yin H., Cheng L., Langenbach R., Ju C. Prostaglandin I(2) and E(2) mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury. Hepatology (2007) 45 159 169.
27. Ariosto F., Riggio O., Cantafora A. et al. Carbon tetrachloride-induced experimental cirrhosis in the rat: a reappraisal of the model. Eur. Surg. Res. (1989) 21 280 286.
28. Blondé-Cynober F., Plassart F., Rey C. et al. Assessment of the carbon tetrachloride-induced cirrhosis model for studies of nitrogen metabolism in chronic liver disease. Ann. Nutr. Metab. (1994) 38 238 248.
29. Schuppan D., Krebs A., Bauer M., Hahn E.G. Hepatitis C and liver fibrosis. Cell Death Differ. (2003) 10 S59 S67.
30. Iredale J.P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Invest. (2007) 117 539 548.
31. Sahu S.C. (Ed.). Hepatotoxicity: from genomics to in vitro and in vivo models. John Wiley & Sons, Ltd, West Sussex, 2007, pp. 121 124.
32. 1 or anti-TNF-alpha is associated with a reduction of TNF-R1 expression in hepatocytes. Scand. J. Gastroenterol. (2003) 38 1169 1175.
33. Totsuka E., Todo S., Zhu Y. et al. Attenuation of ischemic liver injury by prostaglandin E1 analogue, misoprostol, and prostaglandin I2 analogue, OP-41483. J. Am. Coll. Surg. (1998) 187 276 286.
34. Crowley L.V. The Reitman-Frankel colorimetric transaminase procedure in suspected myocardial infarction. Clin. Chem. (1967) 13 482 487.
35. Belfield A., Goldberg D.M. Revised assay for serum phenyl phosphatase activity using 4-amino-antipyrine. Enzyme (1971) 12 561 573.
36. Hafez T., Moussa M., Nesim I., Baligh N., Davidson B., Abdul-Hadi A. The effect of intraportal prostaglandin E1 on adhesion molecule expression, inflammatory modulator function, and histology in canine hepatic ischemia/reperfusion injury. J. Surg. Res. (2007) 138 88 99.
37. Yang H., Majno P., Morel P. et al. Prostaglandin E(1) protects human liver sinusoidal endothelial cell from apoptosis induced by hypoxia reoxygenation. Microvasc. Res. (2002) 64 94 103.
38. Lim S.P., Andrews F.J., O'Brien P.E. Acetaminophen-induced microvascular injury in the rat liver: protection with misoprostol. Hepatology (1995) 22 1776 1781.
39. 1 on d-galactosamine-induced nitrosative stress and cell death in primary culture of human hepatocytes. Prostaglandins Other Lipid Mediat. (2006) 79 245 259.
40. Hemmerling A. The safety of misoprostol. Int. J. Gynecol. Obstet. (2006) 94 S149 S150.
41. Reilly T.P., Brady J.N., Marchick M.R. et al. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem. Res. Toxicol. (2001) 14 1620 1628.
42. Bykov I.L., Palmen M., Rainsford K.D., Lindros K.O. Chronic effects of celecoxib, a cyclooxygenase-2 inhibitor, cause enhanced alcohol-induced liver steatosis in rats. Inflammopharmacol (2006) 14 36 41.
43. Hamada T., Tsuchihashi S., Avanesyan A. et al. Cyclooxygenase-2 deficiency enhances Th2 immune responses and impairs neutrophil recruitment in hepatic ischemia/reperfusion injury. J. Immunol. (2008) 180 1843 1853.
44. Kornberg A., Grube T., Wagner T. et al. Differentiated therapy with prostaglandin E1 (Alprostadil) after orthotopic liver transplantation: the usefulness of procalcitonin (PCT) and hepatic artery resistive index (RI) for the evaluation of early graft function and clinical course. Clin. Chem. Lab. Med. (2000) 38 1177 1180.
45. Huang H.M., Tanaka H., Jin S.W. et al. Effects of prostaglandin E1 infused via the superior mesenteric artery on partially resected, dearterialized canine liver. Osaka City Med. J. (2003) 49 11 19.
46. Hossain M.A., Wakabayashi H., Izuishi K., Okano K., Yachida S., Maeta H. The role of prostaglandins in liver ischemia-reperfusion injury. Curr. Pharm. Des. (2006) 12 2935 2951.
47. Basu S. Carbon tetrachloride-induced lipid peroxidation: eicosanoid formation and their regulation by antioxidant nutrients. Toxicology (2003) 189 113 127.
48. Weber L.W., Boll M., Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit. Rev. Toxicol. (2003) 33 105 136.
49. Muriel P., Mourelle M. Prevention by silymarin of membrane alterations in acute CCl4 liver damage. J. Appl. Toxicol. (1990) 10 275 279.
50. Tanaka N., Tanaka K., Nagashima Y., Kondo M., Sekihara H. Nitric oxide increases hepatic arterial blood flow in rats with carbon tetrachloride-induced acute hepatic injury. Gastroenterology (1999) 117 173 180.
51. Favari L., Perez-Alvarez V. Comparative effects of colchicine and silymarin on CCl4-chronic liver damage in rats. Arch. Med. Res. (1997) 28 11 17.
52. Chrungoo V.J., Singh K., Singh J. Silymarin mediated differential modulation of toxicity induced by carbon tetrachloride, paracetamol and d-galactosamine in freshly isolated rat hepatocytes. Indian J. Exp. Biol. (1997) 35 611 617.
53. Jia J.D., Bauer M., Cho J.J. et al. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J. Hepatol. (2001) 35 392 398.
54. De La Puerta R., Martinez E., Bravo L., Ahumada M.C. Effect of silymarin on different acute inflammation models and on leukocyte migration. J. Pharm. Pharmacol. (1996) 48 968 970.
55. Lucena M.I., Andrade R.J., de la Cruz J.P., Rodriguez Mendizabal M., Blanco E., Sanchez de la Cuesta F. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. Int. J. Clin. Pharmacol. Ther. (2002) 40 2 8.
56. Par A., Roth E., Rumi G., Kovacs Z., Nemes J., Mozsik G. Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C. Orv. Hetil. (2000) 141 1655 1659.